Elevated levels of serum amyloid A indicate poor prognosis in patients with esophageal squamous cell carcinoma

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Wang, Jun Ye ^a   Zheng, Yu Zhen ^a   Yang, Juan ^b   Lin, Yue Hao ^a   Dai, Shu Qin ^a   Zhang, Ge ^c   Liu, Wan Li ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY   (China)

Author keywords

Biomark; Esophageal squamous cell carcinoma; Prognosis; Serum amyloid A

Indexed keywords

AMYLOID A PROTEIN; SERUM AMYLOID A; TUMOR MARKER;

ADULT; AGE; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER SIZE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISTANT METASTASIS; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS SURGERY; FEMALE; GENDER; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOASSAY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NEPHELOMETRY; PREOPERATIVE CARE; PROTEIN BLOOD LEVEL; SURVIVAL RATE; SURVIVAL TIME; ANALYSIS OF VARIANCE; BLOOD; CASE CONTROL STUDY; ESOPHAGUS TUMOR; METABOLISM; MIDDLE AGED; NONPARAMETRIC TEST; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SQUAMOUS CELL CARCINOMA; SURVIVAL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SERUM AMYLOID A PROTEIN; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84865229719     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-365     Document Type: Article

References (35)

1. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002, 420:860-867. 10.1038/nature01322, 2803035, 12490959.
2. McArdle PA, Mir K, Almushatat AS, Wallace AM, Underwood MA, McMillan DC. Systemic inflammatory response, prostate-specific antigen and survival in patients with metastatic prostate cancer. Urol Int 2006, 77:127-129. 10.1159/000093905, 16888416.
3. McMillan DC, Canna K, McArdle CS. Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br J Surg 2003, 90:215-219. 10.1002/bjs.4038, 12555298.
4. Scott HR, McMillan DC, Forrest LM, Brown DJ, McArdle CS, Milroy R. The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer. Br J Cancer 2002, 87:264-267. 10.1038/sj.bjc.6600466, 2364225, 12177792.
5. Yamada T. Serum amyloid A (SAA): a concise review of biology, assay methods and clinical usefulness. Clin Chem Lab Med 1999, 37:381-388.
6. Malle E, De Beer FC. Human serum amyloid A (SAA) protein: a prominent acute-phase reactant for clinical practice. Eur J Clin Invest 1996, 26:427-435. 10.1046/j.1365-2362.1996.159291.x, 8817153.
7. Malle E, Sodin-Semrl S, Kovacevic A. Serum amyloid A: an acute-phase protein involved in tumour pathogenesis. Cell Mol Life Sci 2009, 66:9-26. 10.1007/s00018-008-8321-x, 18726069.
8. Kimura M, Tomita Y, Imai T, Saito T, Katagiri A, Ohara-Mikami Y, Matsudo T, Takahashi K. Significance of serum amyloid A on the prognosis in patients with renal cell carcinoma. Cancer 2001, 92:2072-2075. 10.1002/1097-0142(20011015)92:8<2072::AID-CNCR1547>3.0.CO;2-P, 11596022.
9. Vermaat JS, van der Tweel I, Mehra N, Sleijfer S, Haanen JB, Roodhart JM, Engwegen JY, Korse CM, Langenberg MH, Kruit W, et al. Two-protein signature of novel serological markers apolipoprotein-A2 and serum amyloid alpha predicts prognosis in patients with metastatic renal cell cancer and improves the currently used prognostic survival models. Ann Oncol 2010, 21:1472-1481. 10.1093/annonc/mdp559, 20022911.
10. Wood SL, Rogers M, Cairns DA, Paul A, Thompson D, Vasudev NS, Selby PJ, Banks RE. Association of serum amyloid A protein and peptide fragments with prognosis in renal cancer. Br J Cancer 2010, 103:101-111. 10.1038/sj.bjc.6605720, 2905280, 20531413.
11. Sung HJ, Ahn JM, Yoon YH, Rhim TY, Park CS, Park JY, Lee SY, Kim JW, Cho JY. Identification and validation of SAA as a potential lung cancer biomarker and its involvement in metastatic pathogenesis of lung cancer. J Proteome Res 2011, 10:1383-1395. 10.1021/pr101154j, 21141971.
12. Findeisen P, Zapatka M, Peccerella T, Matzk H, Neumaier M, Schadendorf D, Ugurel S. Serum amyloid A as a prognostic marker in melanoma identified by proteomic profiling. J Clin Oncol 2009, 27:2199-2208. 10.1200/JCO.2008.18.0554, 19307507.
13. Cocco E, Bellone S, El-Sahwi K, Cargnelutti M, Buza N, Tavassoli FA, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Serum amyloid A: a novel biomarker for endometrial cancer. Cancer 2010, 116:843-851. 10.1002/cncr.24838, 2819580, 20041483.
14. Cho WC, Yip TT, Yip C, Yip V, Thulasiraman V, Ngan RK, Lau WH, Au JS, Law SC, Cheng WW, et al. Identification of serum amyloid a protein as a potentially useful biomarker to monitor relapse of nasopharyngeal cancer by serum proteomic profiling. Clin Cancer Res 2004, 10:43-52. 10.1158/1078-0432.CCR-0413-3, 14734450.
15. Pierce BL, Ballard-Barbash R, Bernstein L, Baumgartner RN, Neuhouser ML, Wener MH, Baumgartner KB, Gilliland FD, Sorensen BE, McTiernan A, et al. Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol 2009, 27:3437-3444. 10.1200/JCO.2008.18.9068, 2717751, 19470939.
16. Cho WC, Yip TT, Cheng WW, Au JS. Serum amyloid A is elevated in the serum of lung cancer patients with poor prognosis. Br J Cancer 2010, 102:1731-1735. 10.1038/sj.bjc.6605700, 2883701, 20502455.
17. Chan DC, Chen CJ, Chu HC, Chang WK, Yu JC, Chen YJ, Wen LL, Huang SC, Ku CH, Liu YC, et al. Evaluation of serum amyloid A as a biomarker for gastric cancer. Ann Surg Oncol 2007, 14:84-93.
18. An JY, Fan ZM, Zhuang ZH, Qin YR, Gao SS, Li JL, Wang LD. Proteomic analysis of blood level of proteins before and after operation in patients with esophageal squamous cell carcinoma at high-incidence area in Henan Province. World J Gastroenterol 2004, 10:3365-3368.
19. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003, 349:2241-2252. 10.1056/NEJMra035010, 14657432.
20. Nozoe T, Saeki H, Sugimachi K. Significance of preoperative elevation of serum C-reactive protein as an indicator of prognosis in esophageal carcinoma. Am J Surg 2001, 182:197-201. 10.1016/S0002-9610(01)00684-5, 11574097.
21. Shimada H, Nabeya Y, Okazumi S, Matsubara H, Shiratori T, Aoki T, Sugaya M, Miyazawa Y, Hayashi H, Miyazaki S, et al. Elevation of preoperative serum C-reactive protein level is related to poor prognosis in esophageal squamous cell carcinoma. J Surg Oncol 2003, 83:248-252. 10.1002/jso.10275, 12884238.
22. Crumley AB, McMillan DC, McKernan M, Going JJ, Shearer CJ, Stuart RC. An elevated C-reactive protein concentration, prior to surgery, predicts poor cancer-specific survival in patients undergoing resection for gastro-oesophageal cancer. Br J Cancer 2006, 94:1568-1571. 2361311, 16685271.
23. Fisseler-Eckhoff A. New TNM classification of malignant lung tumors 2009 from a pathology perspective. Pathologe 2009, 30(Suppl 2):193-199.
24. Abdel-Latif MM, Duggan S, Reynolds JV, Kelleher D. Inflammation and esophageal carcinogenesis. Curr Opin Pharmacol 2009, 9:396-404. 10.1016/j.coph.2009.06.010, 19596608.
25. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674. 10.1016/j.cell.2011.02.013, 21376230.
26. Conti P, Bartle L, Barbacane RC, Reale M, Placido FC, Sipe J. Synergistic activation of serum amyloid A (SAA) by IL-6 and IL-1 in combination on human Hep 3B hepatoma cell line. Role of PGE2 and IL-1 receptor antagonist. Immunol Invest 1995, 24:523-535. 10.3109/08820139509066848, 7790046.
27. Glojnaric I, Casl MT, Simic D, Lukac J. Serum amyloid A protein (SAA) in colorectal carcinoma. Clin Chem Lab Med 2001, 39:129-133.
28. Lerut T, Nafteux P, Moons J, Coosemans W, Decker G, De Leyn P, Van Raemdonck D, Ectors N. Three-field lymphadenectomy for carcinoma of the esophagus and gastroesophageal junction in 174 R0 resections: impact on staging, disease-free survival, and outcome: a plea for adaptation of TNM classification in upper-half esophageal carcinoma. Ann Surg 2004, 240:962-972. discussion 972-964, 10.1097/01.sla.0000145925.70409.d7, 1356512, 15570202.
29. Morita M, Yoshida R, Ikeda K, Egashira A, Oki E, Sadanaga N, Kakeji Y, Yamanaka T, Maehara Y. Advances in esophageal cancer surgery in Japan: an analysis of 1000 consecutive patients treated at a single institute. Surgery 2008, 143:499-508. 10.1016/j.surg.2007.12.007, 18374047.
30. Fujiwara H, Suchi K, Okamura S, Okamura H, Umehara S, Todo M, Shiozaki A, Kubota T, Ichikawa D, Okamoto K, et al. Elevated serum CRP levels after induction chemoradiotherapy reflect poor treatment response in association with IL-6 in serum and local tumor site in patients with advanced esophageal cancer. J Surg Oncol 2011, 103:62-68. 10.1002/jso.21751, 21031427.
31. Oka M, Yamamoto K, Takahashi M, Hakozaki M, Abe T, Iizuka N, Hazama S, Hirazawa K, Hayashi H, Tangoku A, et al. Relationship between serum levels of interleukin 6, various disease parameters and malnutrition in patients with esophageal squamous cell carcinoma. Cancer Res 1996, 56:2776-2780.
32. Urieli-Shoval S, Finci-Yeheskel Z, Dishon S, Galinsky D, Linke RP, Ariel I, Levin M, Ben-Shachar I, Prus D. Expression of serum amyloid a in human ovarian epithelial tumors: implication for a role in ovarian tumorigenesis. J Histochem Cytochem 2010, 58:1015-1023. 10.1369/jhc.2010.956821, 2958134, 20713982.
33. Migita K, Kawabe Y, Tominaga M, Origuchi T, Aoyagi T, Eguchi K. Serum amyloid A protein induces production of matrix metalloproteinases by human synovial fibroblasts. Lab Invest 1998, 78:535-539.
34. Li Y, Cai L, Wang H, Wu P, Gu W, Chen Y, Hao H, Tang K, Yi P, Liu M, et al. Pleiotropic regulation of macrophage polarization and tumorigenesis by formyl peptide receptor-2. Oncogene 2011, 30:3887-3899. 10.1038/onc.2011.112, 21499310.
35. De Santo C, Arscott R, Booth S, Karydis I, Jones M, Asher R, Salio M, Middleton M, Cerundolo V. Invariant NKT cells modulate the suppressive activity of IL-10-secreting neutrophils differentiated with serum amyloid A. Nat Immunol 2010, 11:1039-1046. 10.1038/ni.1942, 3001335, 20890286.